Recently, Ivonescimab Injection, independently developed by Akeso-Sino Biopharmaceutical Co., Ltd. and the world's first of its kind, has been officially approved for marketing. Combined with chemotherapy, Ivonescimab Injection is expected to provide a brand-new and highly effective immunotherapeutic regimen for patients with locally advanced or metastatic non-squamous non-small cell lung cancer.

Pathogenic microorganisms can cause a variety of infectious diseases. Large - scale outbreaks of infectious diseases such as Ebola hemorrhagic fever, COVID - 19 infection, and malaria pose severe threats to human life and health, and even trigger social crises. This has driven researchers to seek simpler and more effective methods for treating infectious diseases. Controlling the source of infection, cutting off the route of transmission, and protecting susceptible populations are the keys to preventing and controlling infectious diseases.

Since their discovery, nanobodies have been widely applied in fields such as tumor/neurological disease research and imaging diagnosis. In recent years, researchers have gradually expanded their application to more domains, including food safety and environmental hygiene testing. Recently, researchers have conducted studies on the application of nanobodies in animal husbandry.

Chemokines are a class of small cytokines or signaling proteins secreted by cells. They are so named because of their ability to induce directional chemotaxis of nearby responsive cells. All their receptors belong to the G protein - coupled receptor (GPCR) family with 7 - transmembrane domains, and are mainly expressed in cells such as neutrophils, macrophages, epithelial cells, smooth muscle cells, and fibroblasts ^[1].